TriangleNCT00976911 · CITED IN SOURCE DOCUMENTS
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2022-06-21
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)
Percentage of Participants With Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) Per Modified RECIST (Data Cutoff 14 November 2011)
Duration of Objective Response (Data Cutoff 14 November 2011)
Percentage of Participants Who Died (Data Cutoff 25 January 2013)
Progression Free Survival (PFS; Data Cutoff 14 November 2011)
Overall Survival (Data Cutoff 25 January 2013)
European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Ovarian (OV) 28 Abdominal/Gastrointestinal (AB/GI) Symptom Scale - Percentage of Responders (Data Cutoff 14 November 2011)
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * female patients, \>/=18 years of age * epithelial ovarian, fallopian tube or primary peritoneal cancer * platinum-resistant disease (disease progression within \<6 months of platinum therapy) * EOCG performance status of 0-2 Exclusion Criteria: * non-epithelial tumours * ovarian tumours with low malignant potential * previous treatment with \>2 chemotherapy regimens * prior radiotherapy to the pelvis or abdomen
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- FEMALE
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 milligrams per square meter (mg/m\^2) as a 1-hour intravenous (IV) infusion on Days 1, 8, 15, and 22 every 4 weeks (q4w) OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 every 3 weeks \[q3w\]) OR pegylated liposomal doxorubicin (PLD) 40 mg/m\^2 as a 1 milligram per minute (mg/min) infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.
- intervention Names
- Drug: liposomal doxorubicin
- Drug: paclitaxel
- Drug: topotecan
- label
- Chemotherapy
- type
- ACTIVE_COMPARATOR
- description
- Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion. Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 milligrams per kilogram (mg/kg) IV every 2 weeks (q2w; or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.
- intervention Names
- Drug: Bevacizumab
- Drug: liposomal doxorubicin
- Drug: paclitaxel
- Drug: topotecan
- label
- Chemotherapy + Bevacizumab
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Chemotherapy + Bevacizumab
- description
- 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
- name
- Bevacizumab
- other Names
- Avastin
- type
- DRUG
- arm Group Labels
- Chemotherapy
- Chemotherapy + Bevacizumab
- description
- 40mg/m2 iv every 4 weeks
- name
- liposomal doxorubicin
- type
- DRUG
- arm Group Labels
- Chemotherapy
- Chemotherapy + Bevacizumab
- description
- 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
- name
- paclitaxel
- type
- DRUG
- arm Group Labels
- Chemotherapy
- Chemotherapy + Bevacizumab
- description
- 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
- name
- topotecan
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 361
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Progression free survival was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurs first. Progression was based on tumour assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted.
- measure
- Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011
- description
- PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the RECIST criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted. Time from randomization to occurrence of disease progression or death was measured in months. An event was defined as the earliest progressive disease or death that occurred on or before the cutoff date (14 November 2011), regardless of start of nonprotocol specified anti-cancer therapy or the bevacizumab monotherapy. Disease progression was assessed by investigator according to RECIST or by symptom deterioration, and could not be declared on the basis of rising cancer antigen 125 (CA125) levels alone. Kaplan-Meier methodology was used. 95% CI for median was computed using the method of Brookmeyer and Crowley.
- measure
- Progression Free Survival (PFS; Data Cutoff 14 November 2011)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011
- secondary Outcomes
- description
- Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR defined as complete disappearance of all target and non-target lesions and no new lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. 95% CI computed using the normal approximation to the binomial distribution.
- measure
- Percentage of Participants With Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) Per Modified RECIST (Data Cutoff 14 November 2011)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011
- description
- For randomized participants who achieved an objective response per modified RECIST, duration of objective response was defined as the time from the date of the first occurrence of a CR or PR (whichever occurred first) until the date that progressive disease or death was documented (whichever occurred first). Participants who had an objective response and did not experience disease progression or death by the time of analysis were censored at the time of the last tumor assessment. Summaries of duration of objective response (median and percentiles) were estimated from Kaplan-Meier curves. 95% CI for duration of objective response was computed using the method of Brookmeyer and Crowley.
- measure
- Duration of Objective Response (Data Cutoff 14 November 2011)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011
- measure
- Percentage of Participants Who Died (Data Cutoff 25 January 2013)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013
- description
- Duration of overall survival was defined as the time from randomization to death of any cause. Kaplan-Meier methodology was used. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. 95% CI was computed using the method of Brookmeyer and Crowley.
- measure
- Overall Survival (Data Cutoff 25 January 2013)
- time Frame
- Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013
- description
- The EORTC OV-28 module is a questionnaire that focuses on issues specific to ovarian cancer. It assesses AB/GI symptoms, among others. Participants were asked to indicate the extent to which they experienced AB/GI symptoms in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen/stomach? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms). Participants were considered a responder if they had a 10 point or more reduction in EORTC QLQ-OV28 AB/GI symptom scale score from baseline.
- measure
- European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Ovarian (OV) 28 Abdominal/Gastrointestinal (AB/GI) Symptom Scale - Percentage of Responders (Data Cutoff 14 November 2011)
- time Frame
- Baseline and Weeks 8, 9, 16, 18, 24 and 30 (Data Cutoff 14 November 2011)
Full study description
- brief Summary
- This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.
Source references
- references
- citation
- Newhouse R, Nelissen E, El-Shakankery KH, Rogozinska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3.
- pmid
- 37407274
- type
- DERIVED
- citation
- Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
- pmid
- 37185961
- type
- DERIVED
- citation
- Roncolato FT, Gibbs E, Lee CK, Asher R, Davies LC, Gebski VJ, Friedlander M, Hilpert F, Wenzel L, Stockler MR, King M, Pujade-Lauraine E. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Ann Oncol. 2017 Aug 1;28(8):1849-1855. doi: 10.1093/annonc/mdx229.
- pmid
- 28595285
- type
- DERIVED
- citation
- Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017 Aug 1;28(8):1842-1848. doi: 10.1093/annonc/mdx228.
- pmid
- 28481967
- type
- DERIVED
- citation
- Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, Garcia Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Luck HJ, Gonzalez-Martin A, Kristensen G, Levache CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18.
- pmid
- 27871723
- type
- DERIVED
- citation
- Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, Joly F, de Gregorio N, Arranz JA, Mirza MR, Sorio R, Freudensprung U, Sneller V, Hales G, Pujade-Lauraine E. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014 May 1;32(13):1309-16. doi: 10.1200/JCO.2013.51.4240. Epub 2014 Mar 31.
- pmid
- 24687829
- type
- DERIVED
- citation
- Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.
- pmid
- 24637997
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-20c6671e6098e4508d64
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- 25c471d4-a4c1-4f99-8848-c49ce5b0000a
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- 94b749970a89b3de6a33e5a589a88b4adb6effe1b0ffb2fca5f2510cab1808fc
- payload
- application numbers
- BLA761231
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-20c6671e6098e4508d64
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or prima
- end
- 19638
- exact text
- NCT00976911
- start
- 19627
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/32/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 25c471d4-a4c1-4f99-8848-c49ce5b0000a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 5661fdb9074fbb034143e12e4a4605083cbd33b4e3098809cb7343109493185d
- spl effective time
- 20260127
- spl set id
- 42b4f96e-1f70-2126-e063-6294a90a93e3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-3d8599d2591a56917a5f
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- ca8057b2-9aec-43bc-8525-cf8091433c71
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 8cf2e552669ed1c0e7e7ad1b1cd176d606c2f5da346a7f05a040841c5051f5e3
- payload
- application numbers
- BLA761231
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-3d8599d2591a56917a5f
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or prima
- end
- 19638
- exact text
- NCT00976911
- start
- 19627
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/67/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ca8057b2-9aec-43bc-8525-cf8091433c71
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 5661fdb9074fbb034143e12e4a4605083cbd33b4e3098809cb7343109493185d
- spl effective time
- 20260323
- spl set id
- 6b4040a2-a5c5-4ff0-ab45-935d7e49cf78
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-406acfcf19163375aa88
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
- payload sha256
- 5f6ff33d75ff0850181b6d3d7f2da4629994a7896a568aa0a092a128445e2824
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-406acfcf19163375aa88
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- setting, both during induction and as consolidation therapy. Bevacizumab had first gained approval in the platinum-resistant setting (<a href="/clinicaltrials/NCT00976911">AURELIA</a> trial [NCT00976911]). </p> </section> <section id="_1504"> <h4 id="_1504_toc">Surgery after platinum-based chemotherapy and th
- end
- 189356
- exact text
- NCT00976911
- start
- 189345
- context exact
- and as consolidation therapy. Bevacizumab had first gained approval in the platinum-resistant setting (<a href="/clinicaltrials/NCT00976911">AURELIA</a> trial [NCT00976911]). </p> </section> <section id="_1504"> <h4 id="_1504_toc">Surgery after platinum-based chemotherapy and the addition of HIPEC</h4>
- end
- 189388
- exact text
- NCT00976911
- start
- 189377
- context exact
- :</p> <div class="pdq-content-list"><ol id="_1092"><li>The Avastin Use in Platinum-Resistant Epithelial Ovarian Cancer (<a href="/clinicaltrials/NCT00976911">AURELIA</a> [NCT00976911]) trial was an open-label, randomized trial designed to evaluate the effect of adding bevacizumab to standard chemotherapy in patient
- end
- 312724
- exact text
- NCT00976911
- start
- 312713
- context exact
- lass="pdq-content-list"><ol id="_1092"><li>The Avastin Use in Platinum-Resistant Epithelial Ovarian Cancer (<a href="/clinicaltrials/NCT00976911">AURELIA</a> [NCT00976911]) trial was an open-label, randomized trial designed to evaluate the effect of adding bevacizumab to standard chemotherapy in patients with platinum-resistant
- end
- 312750
- exact text
- NCT00976911
- start
- 312739
- context exact
- ion_8.77">77</a>] This study began before the FDA approved the combination of bevacizumab and pegylated liposomal doxorubicin from the <a href="/clinicaltrials/NCT00976911">AURELIA</a> trial.[<a href="#cit/section_8.68">68</a>]<div class="pdq-content-list"><ul id="_1481"><li>The PFS and OS results failed to show superiority for a
- end
- 320823
- exact text
- NCT00976911
- start
- 320812
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/ff9ceeeae0fbdc33fd.html
- source file sha256
- d626fa717739cf3dda8aebd26e3ffaf109ec1e006da0173aee8007b288898b2c
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:22:10.059252+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 2a71979c192f62071168507c9e3b23e31a4e8fe2e21ca0f7ee294555ff0250c9
- source title
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: May 14, 2025
- datetime
- 2025-05-14T12:00:00Z
- display
- May 14, 2025
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-4eb82b1e479fb26d9676
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 9f48bdd25c140c161362c4be841c97909bac473a68b580b7de6bdf38a6b3d993
- payload
- application numbers
- BLA761268
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-4eb82b1e479fb26d9676
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- ube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 ( NCT00976911 )] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or prim
- end
- 22925
- exact text
- NCT00976911
- start
- 22914
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/78/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 598b7687-6daa-2ce7-e063-6394a90ab429
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 20f4d916b986722fb555e4c9410051bc1746100f6c73529af41036961c7d881c
- spl effective time
- 20260821
- spl set id
- 4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-655e8d10352577dd5fbe
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- e12f075782aee57b9e15cf1b50a1f759f15b883efd3ef8dedadc4b3f0a9fbc65
- payload
- application numbers
- BLA761175
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-655e8d10352577dd5fbe
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or prima
- end
- 23685
- exact text
- NCT00976911
- start
- 23674
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/34/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 2644fd0e-5b94-9120-bdb1-e275d982b249
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- e21069a0948bbce06a85786ddbbc2839d4f9236f5865abba3e3379c45bd1d271
- spl effective time
- 20260311
- spl set id
- 70ab1de6-fb68-aee4-a6cb-f9a0f146687f
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-8e2a469997e0cb1bb1c5
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 35b0adbe73de860c54f436b0a86d94bb3c5db2aac59dc7d89d0711371e71f005
- payload
- application numbers
- BLA761099
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-8e2a469997e0cb1bb1c5
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primar
- end
- 22913
- exact text
- NCT00976911
- start
- 22902
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/27/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8f385b9e-2699-46a0-8c5f-ec1d86cd609d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 774cfec5b812453dac521297deff828caeb90e4c09011e2ec66273f66c607f0b
- spl effective time
- 20260721
- spl set id
- aa27acbd-d117-4350-aeee-17bc2e2c0ca4
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b42eea1a8146957cdfc6
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- payload sha256
- 604dc98a5b4798ad8389987434c056552e8d685d7173fc11ede1b7b1b04e6947
- payload
- application numbers
- BLA125085
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b42eea1a8146957cdfc6
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- ian Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of Avastin were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing Avastin with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary p
- end
- 22560
- exact text
- NCT00976911
- start
- 22549
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00500.json
- source file sha256
- 424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
- source json pointer
- /results/24/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 8debebf6-af94-4ba7-8d67-c801f4ea27eb
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6f9f86027b6f32969be7f30286f48e96e380fd91a3cb2490b51001f709a7db71
- spl effective time
- 20250106
- spl set id
- 939b5d1f-9fb2-4499-80ef-0607aa6b114e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-be076a9597c0e6d2e2d5
- requested nct id
- NCT00976911
- primary nct id
- NCT00976911
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 0381208e02623b2ff159af85d834025578008c3acf9bed56cae25a51598f2827
- payload
- application numbers
- BLA761028
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-be076a9597c0e6d2e2d5
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00976911
- occurrences
- context exact
- Tube, or Primary Peritoneal Cancer Study MO22224 The safety and efficacy of bevacizumab were evaluated in a multicenter, open-label, randomized study [MO22224 (NCT00976911)] comparing bevacizumab with chemotherapy versus chemotherapy alone in patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or prima
- end
- 22952
- exact text
- NCT00976911
- start
- 22941
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/79/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- ea079b8e-24b7-4e03-8340-8078f30f6d98
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- bbf2f2af7cb8babda09095a78b354d15a500aba442759b04c1595566b0870385
- spl effective time
- 20260623
- spl set id
- 0a562b4e-67ce-4bab-852c-d9ee71e55fb8
Preserved source evidence · Not medical advice